ldtЛучевая диагностика и терапияDiagnostic radiology and radiotherapy2079-5343Baltic Medical Education Center10.22328/2079-5343-2017-4-68-74ldt-252Research ArticleЛУЧЕВАЯ ТЕРАПИЯRADIOTHERAPYАНАЛИЗ ДАННЫХ QUANTEC ПО ТОЛЕРАНТНЫМ ДОЗАМ ОБЛУЧЕНИЯ СЕРДЦА И НОВЫЕ КЛИНИЧЕСКИЕ ДАННЫЕANALYSIS OF QUANTEC DATA ON HEART TOLERANT DOSE AND NEW CLINICAL DATAЛебедеваЖ. С.LebedevaZh. S.

кандитат физико-математических наук, медицинкий физик

197022, Санкт-Петербург, ул. Льва Толстого 6/8

zhannamed.phys@mail.ruЛитвиновА. П.LitvinovA. P.

заведующий отделением

радиологическое отделение

ассистент

кафедра рентгенологии и радиационной медицины

197022, Санкт-Петербург, ул. Льва Толстого 6/8

apetrovich@me.comПервый Санкт-Петербургский Государственный Медицинский Университет им. акад. И. П. ПавловаРоссияFirst St. Petersburg State Medical University named after academician I. P. PavlovRussian Federation201722022018046874Copyright © Лебедева Ж.С., Литвинов А.П., 20182018Лебедева Ж.С., Литвинов А.П.Lebedeva Z.S., Litvinov A.P.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://radiag.bmoc-spb.ru/jour/article/view/252

В статье проведен обзор данных о толератных дозах для сердца при облучении различных локализаций. К имеющимся данным, представленным в QUANTEC, добавлены результаты исследований проведенных в последние семь лет. Сделаны выводы о несопоставимости данных, получаемых при облучении области грудины и молочной железы. Вопрос о дозах на сердце при облучении в техниках VMAT пока плохо освещен в дитературе. 

The article reviewed data on tolerant doses to the heart in irradiation of different locations. The results of studies conducted in the last seven years after QUANTEC publication are presented. It was concluded that the data obtained upon irradiation of the sternum and breast cancer are uncomparable. The question about tolerant dose to the heart for VMAT tehnique is poorly covered in the literature.

лучевая терапиятолерантная дозаQUANTECсердцемолочная железапищевод.radiotherapytolerant doseQUANTECheartbreastoesophagusReferencesEmami B., Lyman J., Brown A. et al. Tolerance of normal tissue to therapeutic irradiation, 1991, Vol. 21, рр. 109–122.Emami B., Lyman J., Brown A. et al. Tolerance of normal tissue to therapeutic irradiation, 1991, Vol. 21, рр. 109–122.Marks L.B., Haken R.K., Martel M.K. et al. Guest editor’s introduction to quantec: a users guide, 2010, Vol. 76, No. 3, рр. 1–2.Marks L.B., Haken R.K., Martel M.K. et al. Guest editor’s introduction to quantec: a users guide, 2010, Vol. 76, No. 3, рр. 1–2.Bentzen S.M., Constine L.S., Deasy J.O. et al. Quantitative analyses of normal tissue effects in the clinic (QUANTEC): an introduction to the scientific issues, Int. J. Radiation Oncology Biol. Phys., 2010, Vol. 76, No. 3, рр. 3–9.Bentzen S.M., Constine L.S., Deasy J.O. et al. Quantitative analyses of normal tissue effects in the clinic (QUANTEC): an introduction to the scientific issues, Int. J. Radiation Oncology Biol. Phys., 2010, Vol. 76, No. 3, рр. 3–9.Marks B.L., Yorke E.D., Jackson A. et al Use of normal tissue complication probability models in the clinic, Int. J. Radiation Oncology Biol. Phys., 2010, Vol. 76, No. 3, рр. 10–19.Marks B.L., Yorke E.D., Jackson A. et al Use of normal tissue complication probability models in the clinic, Int. J. Radiation Oncology Biol. Phys., 2010, Vol. 76, No. 3, рр. 10–19.Allen Li X., Alber M., Deasy J.O. et al. The use and QA of biologically related models for treatment planning: short report of the TG-166 of the therapy physics committee of the AAPM, Med. Phys., 2012, Vol. 39, No. 3, рр. 1386–409.Allen Li X., Alber M., Deasy J.O. et al. The use and QA of biologically related models for treatment planning: short report of the TG-166 of the therapy physics committee of the AAPM, Med. Phys., 2012, Vol. 39, No. 3, рр. 1386–409.Lyman J.T. Complication probability as assessed from dose-volume histograms. Radiat. Res., 1985, Vol. 8, рр. 13–19.Lyman J.T. Complication probability as assessed from dose-volume histograms. Radiat. Res., 1985, Vol. 8, рр. 13–19.Kutcher G.J., Burman C., Brewster L. et al. Histogram reduction method for calculating complication probabilities for three-dimensional treatment planning evaluations, Int. J. Radiat. Oncol. Biol. Phys., 1991, Vol. 21, рр. 137–146.Kutcher G.J., Burman C., Brewster L. et al. Histogram reduction method for calculating complication probabilities for three-dimensional treatment planning evaluations, Int. J. Radiat. Oncol. Biol. Phys., 1991, Vol. 21, рр. 137–146.Burman C., Kutcher G.J., Emami B. et al. Fitting of normal tissue tolerance data to an analytic function, Int. J. Radiat. Oncol. Biol. Phys., 1991, Vol. 21, рр. 123–135.Burman C., Kutcher G.J., Emami B. et al. Fitting of normal tissue tolerance data to an analytic function, Int. J. Radiat. Oncol. Biol. Phys., 1991, Vol. 21, рр. 123–135.Niemierko A. A generalized concept of equivalent uniform dose (EUD). Med. Phys., 1999, Vol. 26, рр. 1100.Niemierko A. A generalized concept of equivalent uniform dose (EUD). Med. Phys., 1999, Vol. 26, рр. 1100.Mohan R., Mageras G.S., Baldwin B. et al. Clinically relevant optimization of 3-D conformal treatments. AAPM, 1992, Vol. 19, рр. 933–944.Mohan R., Mageras G.S., Baldwin B. et al. Clinically relevant optimization of 3-D conformal treatments. AAPM, 1992, Vol. 19, рр. 933–944.Van den Bogaard V.A.B., Ta B.D.P., van der Schaaf A. et al. Validation and Modification of a Prediction Model for Acute Cardiac Events in Patients with Breast Cancer Treated with Raditherapy based on Three-Dimensional dose distributions to Cardiac Substructures. J. Clin Oncol., 2017, Vol. 35, No. 11.Van den Bogaard V.A.B., Ta B.D.P., van der Schaaf A. et al. Validation and Modification of a Prediction Model for Acute Cardiac Events in Patients with Breast Cancer Treated with Raditherapy based on Three-Dimensional dose distributions to Cardiac Substructures. J. Clin Oncol., 2017, Vol. 35, No. 11.Varian Developer Forum. https://variandeveloper.codeplex.com/ SourceControl/latest 13. Gagliardi G., Constine L.S., Moiseenko V. et al. Radiation dose-volume effects in the heart. Int. J. Radiation Oncology Biol. Phys., 2010, Vol. 73, No. 3, рр. S77–S85.Varian Developer Forum. https://variandeveloper.codeplex.com/ SourceControl/latest 13. Gagliardi G., Constine L.S., Moiseenko V. et al. Radiation dose-volume effects in the heart. Int. J. Radiation Oncology Biol. Phys., 2010, Vol. 73, No. 3, рр. S77–S85.Nieder C., Schill S., Kneschaurek et al. Influence of different treatment techniques on radiation dose to the LAD coronary artery. Radiat Oncol., 2007, Vol. 2, р. 20.Nieder C., Schill S., Kneschaurek et al. Influence of different treatment techniques on radiation dose to the LAD coronary artery. Radiat Oncol., 2007, Vol. 2, р. 20.RTOG. https://www.rtog.org/CoreLab/ContouringAtlases.aspxRTOG. https://www.rtog.org/CoreLab/ContouringAtlases.aspxJackson A., Yorke E.D., Marks L.B. et al. The lessons of QUANTEC: recommendations for reporting and gathering data on dose-volume dependencies of treatment outcome. Int. J. Radiat. Oncol. Biol. Phys., 2010, Vol. 76, рр. S155–160.Jackson A., Yorke E.D., Marks L.B. et al. The lessons of QUANTEC: recommendations for reporting and gathering data on dose-volume dependencies of treatment outcome. Int. J. Radiat. Oncol. Biol. Phys., 2010, Vol. 76, рр. S155–160.Darby S.C., Ewertz M., McGale P. et al. Risk of ischemic heart disease in women after radiotherapy for breast cancer. N. Engl. J. Med., 2013, Vol. 368, рр. 987–998.Darby S.C., Ewertz M., McGale P. et al. Risk of ischemic heart disease in women after radiotherapy for breast cancer. N. Engl. J. Med., 2013, Vol. 368, рр. 987–998.Schneider U., Ernst M., Hartmann M. The dose-response relationship for cardiovascular disease is not necessarily linear. Radiat Oncol., 2017, Vol. 12, рр. 74.Schneider U., Ernst M., Hartmann M. The dose-response relationship for cardiovascular disease is not necessarily linear. Radiat Oncol., 2017, Vol. 12, рр. 74.Eriksson F., Gagliardi G., Liedberg A. et al. Long-term cardiac mortality following radiation therapy for Hodgkin’s disease: analysis with the relative seriality model. Radiother Oncol., 2000, Vol. 55, рр. 153–162.Eriksson F., Gagliardi G., Liedberg A. et al. Long-term cardiac mortality following radiation therapy for Hodgkin’s disease: analysis with the relative seriality model. Radiother Oncol., 2000, Vol. 55, рр. 153–162.Gagliardi G., Lax I., Ottolenghi A. et al. Long-term cardiac mortality after radiotherapy of breast cancer: application of the relative seriality model. Brit. J. Radiol., 1996, Vol. 69, рр. 839–846.Gagliardi G., Lax I., Ottolenghi A. et al. Long-term cardiac mortality after radiotherapy of breast cancer: application of the relative seriality model. Brit. J. Radiol., 1996, Vol. 69, рр. 839–846.Van Dijk-Peters F.B.J., Sijtsema N.M., Kierkels R.G.J. et al. Validation of a multi-atlas based autosegmentation of the heart in breast cancer patients. Radiother Oncol., 2015, Vol. 115, рр. 132–133.Van Dijk-Peters F.B.J., Sijtsema N.M., Kierkels R.G.J. et al. Validation of a multi-atlas based autosegmentation of the heart in breast cancer patients. Radiother Oncol., 2015, Vol. 115, рр. 132–133.Schultz-Hector S., Trott K.R. Radiation-induced cardiovascular diseases: is the epidemiologic evidence compatible with the radiobiologic data? Int. J. Radiat. Oncol. Biol. Phys. 2007, Vol. 67, рр. 10–18.Schultz-Hector S., Trott K.R. Radiation-induced cardiovascular diseases: is the epidemiologic evidence compatible with the radiobiologic data? Int. J. Radiat. Oncol. Biol. Phys. 2007, Vol. 67, рр. 10–18.Sardaro A., Petruzzelli M.F., D`Errico M.P. et al. Radiation-induced cardiac damage in early left breast cancer patients: risk factors, biological mechanisms, radiobiology, and dosimetric constraints. Radiother. Oncol., 2012, Vol. 103, рр. 133–142.Sardaro A., Petruzzelli M.F., D`Errico M.P. et al. Radiation-induced cardiac damage in early left breast cancer patients: risk factors, biological mechanisms, radiobiology, and dosimetric constraints. Radiother. Oncol., 2012, Vol. 103, рр. 133–142.Beukema J.C., van Luijk P., Widder J. et al. Is cardiac toxicity a relevant issue in the radiation treatment of esophageal cancer? Radiotherapy and Oncology, Vol. 114, рр. 80–85.Beukema J.C., van Luijk P., Widder J. et al. Is cardiac toxicity a relevant issue in the radiation treatment of esophageal cancer? Radiotherapy and Oncology, Vol. 114, рр. 80–85.Wei X., Liu H.H., Tucker S.L., Wang S. et al. Risk factors for pericardial effusion in inoperable esophageal cancer patients treated with definitive chemoradiation therapy. Int J. Radiat Oncol Biol Phys., 2008, Vol. 70, рр. 707–714.Wei X., Liu H.H., Tucker S.L., Wang S. et al. Risk factors for pericardial effusion in inoperable esophageal cancer patients treated with definitive chemoradiation therapy. Int J. Radiat Oncol Biol Phys., 2008, Vol. 70, рр. 707–714.Konski A., Li T., Christensen M., Cheng J.D. et al. Symptomatic cardiac toxicity is predicted by dosimetric and patient factors rather than changes in 18F-FDG PET determination of myocardial activity after chemoradiotherapy for esophageal cancer. Radiother Oncol., 2012, Vol. 104, рр. 72–77.Konski A., Li T., Christensen M., Cheng J.D. et al. Symptomatic cardiac toxicity is predicted by dosimetric and patient factors rather than changes in 18F-FDG PET determination of myocardial activity after chemoradiotherapy for esophageal cancer. Radiother Oncol., 2012, Vol. 104, рр. 72–77.Ghobadi G., van der Veen S., Bartelds B. et al. Physiological interaction of heart and lung in thoracic irradiation. Int. J. Radiat. Oncol. Biol. Phys., 2012, Vol. 84, No. 5, рр. 639–646.Ghobadi G., van der Veen S., Bartelds B. et al. Physiological interaction of heart and lung in thoracic irradiation. Int. J. Radiat. Oncol. Biol. Phys., 2012, Vol. 84, No. 5, рр. 639–646.Cella L., Liuzzi R., Conson M. Modeling of Heart Valve Dysfunction in Hodgkin Lymphoma Survivors. Int. J. Radiat. Oncol. Biol. Phys., 2013, Vol. 87, No. 2, рр. 304–331.Cella L., Liuzzi R., Conson M. Modeling of Heart Valve Dysfunction in Hodgkin Lymphoma Survivors. Int. J. Radiat. Oncol. Biol. Phys., 2013, Vol. 87, No. 2, рр. 304–331.

The authors declare that there are no conflicts of interest present.